Items tagged with Vaccines
The purpose of the report, based on the TB ECAB (European Community Advisory Board) meeting held in Brussels between May 17-19, 2013 is to inform ECAB and community advocates on HIV/TB treatment, care and research advocacy, in order to increase the capacity of the ECAB members and partners to get further involved in TB drugs, diagnostics development and access, and to identify key advocacy priorities.
Scarce global funding for the development of new tuberculosis vaccines forces to select rigorously in the current portfolio of TB vaccine candidates. Because it’s not possible to support all vaccine candidates, TBVI developed an instrument to make the right decisions in order to advance vaccine development: portfolio management. This is announced in TBVI's annual report, released today.
13th - 17th October 2014, International Livestock Research Institute, Nairobi, Kenya
New molecular basis of attenuation and immunogenicity of the tuberculosis vaccine candidate MTBVAC described (post)
The tuberculosis vaccine candidate MTBVAC is the only vaccine in clinical trials based on an attenuated Mycobacterium tuberculosis strain of human origin. In various animal models, MTBVAC confers a similar attenuation and greater immunity than the current BCG vaccine against tuberculosis. BCG is a Mycobacterium bovis derivative, isolated from cows in the early twentieth century, which does not protect against respiratory forms of tuberculosis. MTBVAC is developed by TBVI’s research partner University of Zaragoza in collaboration with biopharmaceutical company Biofabri.
Scissoring the lipids (post)
A new strategy which enables molecules to be disconnected essentially anywhere, even remote from functionality, is described by researchers from the University of Bristol in Nature Chemistry. The method is now being developed to explore the possibility of creating a tuberculosis (TB) vaccine.
Although only effective in countries more than 40° latitude away from the equator
TBVI's research partner Norwegian University of Life Sciences receives a research grant of 10.2 million Norwegian Crowns (1.25 million euro) for the development of new TB vaccines. The grant is awarded by the Norwegian Programme for Global Health and Vaccination Research (GLOBVAC) for the period 1 September 2014- 31 August 2018. The research activitities will be executed in close collaboration with the TBVI network.
Researchers have found no evidence that delayed administration of the bacillus Calmette-Guérin (BCG) vaccination for tuberculosis (TB) affects immune responses to the vaccine, according to a South African study published online August 8 in the Journal of Infectious Diseases.
Meta-analysis of 14 studies indicated that BCG vaccination protects against Mycobacterium tuberculosis infection in children under 16 years old, while a six-study analysis determined that the vaccine protects and against progression from infection to active disease.
Mycobacterium tuberculosis infects a third of the world's population every year, causing 8·6 million new cases and 1·3 million deaths annually (1).BCG, a live-attenuated bacterial vaccine developed in the 1920s, is still used to vaccinate most children worldwide. Although BCG protects infants from severe disseminated disease, it cannot prevent infection. Especially in developing countries, pulmonary tuberculosis can develop mostly during adolescence, and has a high mortality rate in patients who are co-infected with HIV. So far, the development of vaccines that outperform BCG has been difficult.
Page 2 of 8 · Total posts: 0←First 1 2 3 Last→